Unicycive's OLC NDA Under FDA Review Amid Financial Losses
By ATTN Desk · Editorial oversight: Sean Han
Unicycive Therapeutics Inc (Nasdaq: UNCY)
Introduction
Unicycive Therapeutics Inc (“Unicycive”) is a clinical-stage biotechnology company founded in 2016 and headquartered in Los Altos, California. The company focuses on developing treatments for kidney diseases, particularly therapies for chronic kidney disease (CKD) patients on dialysis and acute kidney injury. In Korean, the company is named 유니사이클 테라핀틱스.
Corporate Structure and Experience
- Founded: 2016
- Headquarters: Los Altos, CA
- Employees: 11–50 (LinkedIn profile)
- Management Team:
- Shalabh Gupta, M.D. – Founder, Chief Executive Officer, President, and Chairman. Previously CEO of Biocycive Inc., commercial strategist at Genentech, and equity researcher at UBS and Rodman & Renshaw.
- John Townsend – Chief Financial Officer. Over 25 years of experience in public and private company finance, including roles at Guardion Health Sciences and Cytori Therapeutics. Certified Public Accountant (California).
- Douglas Jermasek, MBA – Executive Vice President, Corporate Strategy. Over 25 years of commercial leadership experience at firms such as Genzyme (Sanofi) and Akebia Therapeutics.
Recent Developments and News
U.S. FDA and Regulatory Milestones
- June 28, 2025: Prescription Drug User Fee Act (PDUFA) target action date for New Drug Application (NDA) of oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients on dialysis.
- November 11, 2024: FDA accepted the NDA for OLC via the 505(b)(2) pathway; waiver of application fees estimated at $4 million.
Financial Reporting and Corporate Actions
- March 31, 2025: Full-Year 2024 Financial Results:
- Licensing revenues decreased by $0.7 million year-over-year.
- R&D expenses totaled $20.0 million (2023: $12.9 million).
- G&A expenses totaled $12.1 million (2023: $8.5 million).
- Net loss amounted to $37.8 million (2023: $31.4 million).
- June 9, 2025: Annual Meeting of Stockholders:
- Four directors were elected to serve until the 2026 meeting.
- Grassi & Co. CPAs, P.C. was ratified as the independent registered public accounting firm for the fiscal year ended December 31, 2025.
Analyst Coverage and Price Targets
- April 21, 2025: Guggenheim initiated coverage with a Buy recommendation.
- Average one-year price target: $5.78 (range: $3.03–$9.45), reflecting a potential upside from a previous closing price of $0.61.
- Projected annual revenue: $13 million; expected non-GAAP EPS: -$1.09.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share price (2025-06-10) | $0.5097 (–43.37% vs. prior) |
| Volume (2025-06-10) | 3,506,743 shares |
| 52-Week range | $0.2020–$1.1000 |
| Market Cap (intraday) | $108.6 million |
| Cash (most recent quarter) | $19.8 million |
| Total Debt/Equity (most recent quarter) | 4.86% |
| R&D Expenses (2024) | $20.0 million |
| G&A Expenses (2024) | $12.1 million |
| Net Loss (2024) | $37.8 million (–$0.56/sh) |
| Average 1-Year Price Target | $5.78 |
- Cash Runway and Investment: With $19.8 million in cash as of the most recent quarter and an R&D burn rate of $20.0 million in 2024, Unicycive's funding requirements will depend on milestone payments and potential capital raises prior to a late-2025 commercial launch.
- Strategic Pipeline:
- Oxylanthanum Carbonate (OLC): A next-generation phosphate binder designed to reduce the pill burden for patients.
- UNI-494: A late-preclinical asset aimed at acute kidney injury; Phase 1 tolerability data presented in October 2024.
- Partnerships: Exclusive license agreement with Lotus Pharmaceutical for Korea, with potential milestone payments up to $3.7 million plus royalties.
Market Position and Industry Context
- Hyperphosphatemia Market: The global opportunity is estimated to exceed $2.5 billion, with more than $1 billion from U.S. dialysis patients.
- Unmet Need: Approximately 75% of U.S. dialysis patients struggle to reach guideline-recommended phosphorus levels due to pill burden and tolerability issues associated with existing treatments.
- Competitive Landscape: Current phosphate binders include lanthanum carbonate chewable tablets. OLC aims to differentiate itself by offering a solution with potentially improved tolerability and usability.
- Analyst Sentiment: Institutional ownership increased by 31.9% in the previous quarter, with 41 funds reporting positions as of April 2025, indicating increased investor interest.
tl;dr
- OLC NDA under FDA review with a PDUFA date of June 28, 2025; if approved, commercial launch is anticipated for late 2025.
- Share price closed at $0.5097 on June 10, 2025, after a 43.4% decline; market capitalization stands at $108.6 million.
- Guggenheim initiated coverage on April 21, 2025, with an average one-year price target of $5.78, suggesting high potential upside.
- Full-year 2024 net loss recorded at $37.8 million; approximately $19.8 million in cash supports ongoing development and pre-commercial activities.